Near-Perfect Agreement with In-Lab PSG

DormoVision X™: Near-Perfect Agreement with In-Lab PSG

The gold standard for diagnosing sleep disorders has always been in-lab polysomnography (PSG). While reliable, traditional PSG involves high costs, limited accessibility, and patient discomfort. DormoVision X™ (formerly Vlab) bridges this gap. In a peer-reviewed head-to-head validation study, DormoVision X™ demonstrated substantial equivalence to the Nox A1 PSG system, proving that clinical precision and patient comfort are no longer mutually exclusive. Clinically validated to deliver 96.6% agreement with in-lab PSG, it proves that accuracy and patient comfort can go hand in hand.

Validation Study Outline

In a prospective, comparative study published in Sleep and Breathing, DormoVision X™ was evaluated against the Nox A1 gold-standard system where 47 people completed the head-to-head comparison between the DormoVision X and the in-lab PSG. The findings confirm the device’s high diagnostic reliability:

• AHI Precision: The mean Apnea-Hypopnea Index (AHI) showed no statistically significant difference between systems (21.7 events/h for DormoVision X vs. 21.5 events/h for PSG; p=0.7).

• High Severity Agreement: Severity classification (Normal, Mild, Moderate, Severe) achieved a Cohen’s Kappa of 0.97, indicating “almost perfect” agreement in clinical diagnosis.

• Bland-Altman Analysis: The mean difference in AHI was just -0.19 events/h, with tight limits of agreement, ensuring consistent results across a wide range of patient severities.

• Full Signal Integrity: Strong correlations were observed across all signals, including EEG, EOG, EMG, and respiratory effort, with the only minor variance found in REM latency.

Why This Equivalence Matters for Sleep Clinics

• Uncompromising Accuracy: With a 0.97 Kappa score, clinicians can trust that patients will receive the same severity classification at home as they would in a controlled lab environment.

• Type II Capability at Home: DormoVision X™ captures the full breadth of PSG data—including sleep staging and respiratory effort—without the “first-night effect” caused by intrusive lab wiring.

• Operational Efficiency: Eliminate the logistics of nasal cannulas and complex hookups. The wireless, mask-based design is rated 4+/5 for comfort, reducing the likelihood of failed studies and data loss.

• Standardized Scoring: Data is exported in standard EDF formats, allowing for manual scoring or AI-assisted analysis using existing clinical workflows.

Comprehensive Signal Fidelity and Diagnostic Depth

The DormoVision X™ transcends the limitations of traditional Home Sleep Apnea Testing (HSAT) by providing a high-fidelity, 38-channel signal suite—comprising 29 direct and 9 derived channels. By capturing a full neurophysiological profile, including 6-channel EEG, EOG, and multi-site EMG, the system moves beyond the “estimated” metrics of Level III devices. For the clinician, this translates to the measurement of actual Total Sleep Time (TST) rather than mere recording time. This technical depth allows for the precise identification of REM-related pathologies, periodic limb movement disorders, and complex insomnia, providing a level of diagnostic nuance previously reserved for the controlled lab environment.

–

Validation Through Statistical Agreement

The clinical utility of a diagnostic tool is defined by its reliability across the severity spectrum. In head-to-head validation against the Nox A1 gold-standard system, the DormoVision X™ demonstrated a Cohen’s Kappa of 0.97 for sleep apnea severity classification. This “almost perfect” statistical agreement ensures that the transition from lab to home does not result in diagnostic drift. With a mean AHI difference of only -0.19 events per hour, clinicians can prescribe with total confidence, knowing that the home-acquired data is highly comparable to in-lab PSG.

–

Ecological Validity and the Patient Experience

One of the primary barriers to accurate sleep data is the “first-night effect,” where the intrusive nature of lab wiring and the unfamiliar environment fragment the patient’s natural sleep architecture. The DormoVision X™ addresses this through a wireless, mask-integrated design that eliminates the need for nasal cannulas and dozens of body leads. By facilitating a Type II PSG in the patient’s own bed, the system captures data with high ecological validity—recording the patient’s sleep as it occurs in their daily life. This patient-centric approach results in higher compliance, lower study failure rates, and a more authentic representation of the patient’s physiological state.

–

Seamless Integration and Operational Scalability

Efficiency in a modern sleep lab requires a bridge between high-quality data and streamlined workflows. The DormoVision X™ ensures this, as seen in “Evaluation of the Usability and Performance Assessment of the DormoTech VLAB Device as a Home Sleep Test,” by utilizing standardized EDF (European Data Format) exports, making the data fully interoperable with existing manual scoring platforms and emerging AI-assisted analysis tools. This allows sleep centers to scale their diagnostic capacity exponentially without the capital expenditure of physical lab expansion. By decentralizing the point of care while maintaining a centralized, high-standard scoring process, clinics can reach more patients faster without compromising the integrity of the diagnostic output.

–

Comfort Without Compromise

Sleep medicine no longer has to choose between accuracy and accessibility. DormoVision X™ offers the comfort of wireless, patient-friendly design and the confidence of 97% near perfect agreement with gold-standard PSG. For clinics and innovators alike, it provides a path toward scalable, high-quality sleep diagnostics that meet the needs of both patients and providers.

DormoVision X™ is redefining of what modern sleep diagnostics can be.

Dormotech Ltd. (2025). Validation of Dormotech Sleep Analysis Solution (Dormotech) (ClinicalTrials.gov Identifier: NCT06224972). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT06224972

Dormotech Medical. (2024). The Accuracy of the Dormotech VLAB During Stable Hypoxia Plateaus (ClinicalTrials.gov Identifier: NCT06516809). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT06516809